Cancer Research Meeting Calendar Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 67, 1270, February 1, 2007. doi: 10.1158/0008-5472.CAN-06-2184
© 2007 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jazirehi, A. R.
Right arrow Articles by Bonavida, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jazirehi, A. R.
Right arrow Articles by Bonavida, B.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy

Ali R. Jazirehi, Mario I. Vega and Benjamin Bonavida

Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California

Requests for reprints: Benjamin Bonavida, Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles School of Medicine, A2-060A CHS, 10833 Le Conte Avenue, Los Angeles, CA 90024-1747. Phone: 310-825-2233; Fax: 310-206-3865; E-mail: bbonavida{at}mednet.ucla.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Immunotherapy with rituximab (chimeric anti-CD20 monoclonal antibody, Rituxan), alone or in conjunction with chemotherapy, has significantly improved the treatment outcome of lymphoma patients. Via an elusive mechanism, a subpopulation of patients becomes unresponsive and/or relapses. To recapitulate various aspects of acquired resistance, rituximab-resistant (RR) clones were established from lymphoma lines and compared with parental cells. Surface CD20 expression was diminished in the clones. The clones neither responded to rituximab-mediated growth reduction or complement-dependent cytotoxicity nor underwent apoptosis in response to cross-linked rituximab. Rituximab failed to chemosensitize the RR clones, which exhibited constitutive hyperactivation of the nuclear factor-{kappa}B and extracellular signal-regulated kinase 1/2 pathways, leading to overexpression of B-cell lymphoma protein 2 (Bcl-2), Bcl-2–related gene (long alternatively spliced variant of Bcl-x gene), and myeloid cell differentiation 1 and higher drug resistance. Unlike parental cells, rituximab neither inhibited the activity of these pathways nor diminished the expression of resistant factors. Pharmacologic inhibitors of the survival pathways or Bcl-2 family members reduced the activity of these pathways, diminished antiapoptotic protein expression, and chemosensitized the RR clones. These novel in vitro results denote that continuous long-term rituximab exposure culminates in RR clones that do not respond to rituximab-mediated effects, have altered cellular signaling dynamics, and exhibit different genetic and phenotypic properties compared with parental cells. The data also reveal that although RR clones exhibit higher resistance to rituximab and cytotoxic drugs, these clones can be chemosensitized following treatment with pharmacologic inhibitors (e.g., dehydroxymethylepoxyquinomicin, bortezomib, PD098059) that target survival/antiapoptotic pathways. The findings also identify intracellular targets for potential molecular therapeutic intervention to increase treatment efficacy. The significance and potential clinical relevance of the findings are discussed. [Cancer Res 2007;67(3):1270–81]


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The lymphatic cancers known as non–Hodgkin's lymphoma (NHL) are steadily increasing in prevalence worldwide. Although NHLs initially respond to a variety of therapeutic modalities, they exhibit an unremitting relapsing nature and are essentially considered incurable. This pattern of inevitable failure of standard therapies is due to the emergence of drug-resistant variants that highlight the urgent need for the design of new treatment regimens. Monoclonal antibodies (mAb) targeted against specific surface markers that are less systematically toxic and less myelosuppressive have provided an alternative therapeutic approach. About 80% to 85% of NHLs are of B-cell origin and ~95% of these cells express surface CD20 (1, 2).

The B-cell–specific surface marker CD20 (3) does not circulate in the plasma as a free protein, which could potentially block antibody binding to the cells (4). It is also neither internalized upon antibody ligation (5) nor is shed from the cell surface (6)—properties that make CD20 an ideal target for immunotherapy of NHL. The chimeric mouse anti-human CD20 mAb rituximab (IgG1{kappa}) binds with high affinity to CD20-expressing cells. It is the first Food and Drug Administration–approved mAb for NHL treatment (7).

Rituximab has been an important addition to the therapeutic armamentarium against low-grade follicular NHL (8). Furthermore, its usefulness alone or combined with chemotherapy is considered as first-line therapeutic option for other types of hematologic malignancies (9–11) improving patient survival. Its usage is also extended to other pathologic states culminating in long-lasting response (12–15). Rituximab exerts significant antitumor activity in vivo (1) via inhibition of cell proliferation or triggering multiple cell-damaging mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity (CDC), and apoptosis (16, 17). It also augments the cytotoxic effects of drugs on drug-resistant NHL B-cells (18). Nonetheless, the contribution of these mechanisms on primary normal and malignant B-cells in vivo and the molecular mechanisms of rituximab action need to be defined.

We proposed that modifications of signaling pathways by rituximab may be crucial for its chemosensitizing attribute. To this end, we have recently reported that rituximab, via inhibition of nuclear factor-{kappa}B (NF-{kappa}B) and extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) pathways, reduces Bcl-xL [B-cell lymphoma protein 2 (Bcl-2)–related gene (long alternatively spliced variant of Bcl-x gene)] expression and chemosensitizes NHL B-cells (19, 20). Activation of NF-{kappa}B and ERK1/2 pathways are emerging as major mechanisms of tumor cell drug resistance and induce their rapid proliferation. Thus, interruption of these pathways is a target for therapeutic intervention and may confer drug sensitivity (21, 22), which has proven successful in enhancing the apoptotic effects of tumor necrosis factor (TNF)-{alpha} and CPT-11 resulting in tumor regression in vivo (23). Inhibition of NF-{kappa}B and ERK1/2 pathways was shown by decrease in phosphorylation and kinase activities of the signaling molecules and reduced NF-{kappa}B and activator protein-1 (AP-1) DNA-binding ability concomitant with reduction in the expression of their common downstream target Bcl-xL (24).

The superior efficacy of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) + rituximab compared with CHOP alone in elderly diffuse large B-cell lymphoma patients was reported, where the combination therapy resulted in higher rates of complete remission and survival (2) and also increases overall survival in aggressive Bcl-2–positive and Bcl-2–negative patients (25). Despite its well-established clinical efficacy, a subpopulation of patients, via an elusive mechanism, does not respond to rituximab and/or acquires resistance upon long-term rituximab therapy (16, 17). Based on previous reports, we hypothesized that development of rituximab resistance may be related to failure of tumor cells to respond to rituximab-mediated signaling. Further, the unresponsiveness of the cells to drug therapy (alone or combined with rituximab) may be due to hyperactivation of survival signaling pathways and up-regulation of resistant factors. Due to challenges in obtaining patient-derived specimens for analysis, and to recapitulate various aspects of acquired rituximab-resistant (RR) situations, rituximab-refractory clones were generated (26). Using a battery of functional and biochemical assays, representative clones were compared with parental cells to examine alterations in rituximab-mediated effects and to examine the above hypotheses. Different RR clones have also been established and analyzed (27). The following objectives were investigated: (a) phenotypic and functional properties of RR clones (e.g., differences regarding CD20 surface expression, proliferation, CDC, cross-linked rituximab-mediated apoptosis); (b) chemosensitivity of the clones and chemosensitization by rituximab; (c) activation status of ERK1/2 and NF-{kappa}B pathways; (d) expression of Bcl-2 family members; and (e) effects of various inhibitors of survival pathways on reversal of chemoresistance. The results are concordant with hypotheses and reveal that RR clones display different biochemical and functional properties compared with wild-type (WT) cells. These differences and potential clinical significance of the observations are discussed.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell Lines and Clones
CD20+ human Burkitt's lymphoma B-cell lines Daudi and Ramos were obtained from the American Type Culture Collection (Bethesda, MD). For the generation of RR clones, WT cells were grown in the presence of stepwise increasing concentrations of rituximab (5–20 µg/mL for 10 weeks). Single cells were then subjected to three consecutive rounds of limiting dilution analysis (26). Single cells were propagated and maintained in RPMI 1640 supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS; ref. 28). Clones were supplemented with 20 µg/mL rituximab weekly and grown in rituximab-free medium at least 1 week before analysis. Cultures were incubated in controlled atmosphere incubator at 37°C with saturated humidity at 0.5 x 106/mL.

Reagents
Paclitaxel, cisplatin, etoposide (VP-16), Adriamycin, and vincristine were purchased from Sigma (St. Louis, MO) and were diluted in DMSO. The concentration of DMSO did not exceed 0.1% in any experiment. Mouse anti–Bcl-xL and anti–myeloid cell differentiation 1 (Mcl-1) mAbs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and anti–Bcl-2 mAb was purchased from DAKO (Carpinteria, CA). Mouse anti–p-I{kappa}B-{alpha} (Ser32/36) and antiactin mAbs were obtained from Imgenex (San Diego, CA) and Chemicon (Temecula, CA). Rabbit phosphorylated inhibitor of {kappa}B kinase complex (IKK) {alpha}/ß (Ser180/181) antibody was obtained from Cell Signaling (Beverly, MA). Rabbit anti–p-ERK1/2 (Thr185/Tyr187) antibody, MAPK kinase substrate-4 (amino acids 172–192) and PD098059 were obtained from Biosource (Camarillo, CA). 2MAM-A3 was purchased from Biomol (Plymouth, PA). Dehydroxymethylepoxyquinomicin (DHMEQ) was provided by Dr. K. Umezawa (Keio University, Yokohama, Japan). Rituximab and bortezomib were procured commercially.

Surface CD20 Expression
Cells (2 x 106) were washed twice with ice-cold 1x PBS and stained with 1 µg mouse anti-human CD20 mAb (IDEC Pharmaceuticals, San Diego, CA) or isotype control (pure IgG1; 20 min on ice, light protected). Then, the cells were washed twice with ice-cold 1x PBS, stained with FITC-labeled secondary antibody (30 min on ice, light protected), and subjected to fluorescence-activated cell sorting (FACS) analysis.

Immunoblot Analysis
Cells (107) were grown either in complete medium or in complete medium supplemented with various inhibitors. Cells were lysed at 4°C in radioimmunoprecipitation assay buffer [50 mmol/L Tris-HCl (pH 7.4), 1% NP40, 0.25% sodium deoxycholate, 150 mmol/L NaCl] supplemented with one tablet of protease inhibitor cocktail (Complete Mini, Roche, Indianapolis, IN). A detergent-compatible protein assay kit (Bio-Rad, Hercules, CA) was used to determine protein concentration. An aliquot of total protein lysate was diluted in an equal volume of 2x SDS sample buffer, boiled for 10 min, and cell lysates were electrophoresed on 12% SDS-PAGE gels. Western blot was carried out as described (28). The relative intensity of bands, hence, the relative alterations in protein expression, was assessed by densitometric analysis of digitized images using public domain NIH image program.1

Assessment of Apoptosis
DNA fragmentation assay. Percentage of apoptotic cells was determined by evaluation of propidium iodide–stained preparations of cells using an EpicXL flow cytometer. Cellular debris was excluded from analysis by raising the forward scatter threshold, and DNA content of the intact nuclei was recorded on a logarithmic scale (29). Percentage apoptosis is represented as percentage of hypodiploid cells accumulated at sub-G0 phase of the cell cycle.

Evaluation of active caspase-3 levels. Levels of active caspase-3 were evaluated with FITC-labeled anti–active caspase-3 mAb (PharMingen, San Diego, CA; ref. 28).

Assessment of Viable Cell Recovery
Viable cell recovery was assessed using standard 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) assay kit (Roche) that measures metabolic activity of viable cells (30). Percentage cell recovery was calculated using background-corrected reading as follows: % cell recovery = [(absorbance of sample wells / absorbance of untreated cells)] x 100.

Electrophoretic Mobility Shift Analysis
The DNA-binding abilities were evaluated using biotin-labeled oligonucleotide AP-1 (5'-CGCTTGATGACTCAGCCGGAA-3'; ref. 31) and NF-{kappa}B (5'-AGTTGAGGGGACTTTCCCAGGC-3') probes (32) using an electrophoretic mobility shift assay (EMSA) kit (Panomics, Inc., Redwood City, CA) according to the manufacturer's instructions. Ten micrograms of nuclear extracts were subjected to denaturing 5% PAGE and were developed (19, 20).

Immunocomplex Kinase Assay
The kinase activity of IKK and MAP/ERK kinase 1/2 (MEK1/2) was assessed by their ability to phosphorylate I{kappa}B-{alpha} (Ser32/36) and MAPK kinase substrate 4 (Thr185/Tyr187) using a slightly modified version of previous methods (19, 20, 33).

Quantitative Real-time PCR
Samples were analyzed in triplicate with iQ SYBR Green Supermix using iCycler Sequence Detection System (Bio-Rad). Total RNA was extracted from 107 cells for each condition with 1 mL per sample of STAT-60 reagent and quantified by 3.1.2 NanoDrop ND-1000 spectrophotometer. Total RNA (3 µg) was reversed to first-stranded cDNA for 1 h at 42°C with 200 units SuperScript II reverse transcriptase and 20 µmol/L random hexamer primers. Amplification of 2.5 µL of cDNAs was done using gene-specific primers. Internal control for equal cDNA loading in each reaction was assessed using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers. Amplicons were resolved by 2% gels for confirmation and were of expected size. Percentages of expression of each molecule were calculated with the assumption that control samples were considered as 100%.

Statistical Analysis
Assays were set up in triplicates, and results were expressed as mean ± SD. Statistical analysis and P values were calculated by a two-tailed paired t test with a 95% confidence interval for determination of significance of differences between treatment groups (P < 0.05, significant). ANOVA was used to test significance among the groups using InStat 2.01 software.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Phenotypic and Functional Properties of the RR Clones
Diminished surface CD20 expression and failure to respond to rituximab-mediated inhibition of cell growth and apoptosis following cross-linking. WT cells and Ramos-RR1 and Daudi-RR1 clones were stained with isotype control (pure IgG1; Fig. 1A, gray lines ) or FITC-labeled anti-CD20 mAb (IgG1 subtype; solid black lines) and were subjected to FACS analysis. As measured by mean fluorescence intensity, WT cells show significant CD20 surface expression whereas the clones exhibit ~40% to 50% reduction in surface CD20 (Ramos, 468.4 ± 14.0 versus 264 ± 9.6; Daudi, 346 ± 11.4 versus 156.4 ± 10.2). Similar results were obtained in multiple independent experiments with other Ramos-RR and diffuse large B-cell lymphoma RR clones (data not shown), suggesting that continuous rituximab treatment results in diminished, but not complete loss of, surface CD20 expression on RR clones.


Figure 1
View larger version (55K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. A, surface expression of CD20 on RR1 clones. Cells (2 x 106) were stained with 1 µg anti-CD20 mAb (IgG1 subtype; solid black lines) or isotype control (pure IgG1; gray lines) and subsequently with FITC-labeled secondary antibodies and then analyzed by FACS. The intensity of surface CD20 expression was measured by the mean fluorescence intensity (MFI; n = 3). B, rituximab inhibits the proliferation of the WT but not the RR clones. Cells were either left untreated or treated with various concentrations of rituximab (20, 50, and 100 µg/mL, 24 h) and 104 cells in triplicates were used in standard XTT assay. NS, not significant. C, an aliquot of the above samples was examined microscopically to assess the ability of rituximab to form homotypic aggregation of the clones. D, failure of cross-linked rituximab to induce apoptosis in RR clones. Cells (2 x 106) were either left untreated or treated with antihuman immunoglobulin (Ig), rituximab, or the optimal concentration of cross-linked rituximab (50 µg/mL antihuman immunoglobulin + 20 µg/mL rituximab, 24 h) and subjected to propidium iodide assay for the percentage of apoptotic cells. E, failure of rituximab to mediate CDC in the RR clones. Cells (2 x 106) were either left untreated or treated with human antibody serum (5% and 10%), rituximab, or the combination for 24 h and subjected to propidium iodide staining (without fixing) for the percentage of dead cells. F, failure of rituximab to chemosensitize the RR clones. Cells (2 x 106) were either left untreated or pretreated with various concentrations of rituximab (20, 50, and 100 µg/mL, 24 h). Then, the cells were washed and then grown in complete medium supplemented with paclitaxel (0.1–10 nmol/L, 18 h). Cells were then stained with propidium iodide solution, and apoptosis was assessed by FACS. Samples were set up in duplicates. Columns, mean (n = 2); bars, SD. *, P < 0.05, significant compared with control.

 
To assess the ability of RR clones to respond to growth-inhibitory effects of rituximab, both the WT and the clones were either left untreated or treated with a predetermined concentration of rituximab for WT cells (20 µg/mL, 24 h; ref. 34). An aliquot (104) of cells was used in a standard XTT viability assay. Rituximab exerts an inhibitory effect on the WT cells (Ramos, 27%; Daudi 46%), whereas it fails to reduce the growth of RR clones (Ramos-RR1, 98%; Daudi-RR1, 106%; Fig. 1B, top). Higher concentrations (50 or 100 µg/mL) or longer exposure time (up to 48 h) of rituximab did not alter the phenotype of the clones (Fig. 1B, bottom); thus, 20 µg/mL rituximab (24 h) was used in subsequent studies. Results of the XTT assay were confirmed by trypan blue dye exclusion and FACS (data not shown), which essentially showed that rituximab fails to induce apoptosis or inhibit cell growth in RR clones. Untreated RR clones exhibited homotypic aggregation that remained unaffected by rituximab. In contrast, WT cells grew as suspended nonaggregated cells, and rituximab caused them to form clumps (Fig. 1C). These results suggest that whereas rituximab efficiently lowers the growth rate of the WT cells, it fails to reduce the growth of RR clones even at higher concentrations.

Next, we assessed the ability of cross-linked rituximab to induce apoptosis in RR clones. WT cells and the clones were pretreated with an optimal concentration of cross-linked rituximab (50 µg/mL antihuman immunoglobulin + 20 µg/mL rituximab, 24 h; ref. 35) and were subjected to apoptosis assay. DNA fragmentation assay for apoptosis detection in subsequent experiments was confirmed by measuring active caspase-3 levels (ref. 28; data not shown). Neither rituximab (Ramos-RR1, 11.0 ± 0.8%; Daudi-RR1, 6.7 ± 0.6%) nor the antihuman immunoglobulin (Ramos-RR1, 10.2 ± 1.1%; Daudi-RR1, 12.8 ± 0.5%) alone efficiently killed the cells. However, the combination of the two agents (cross-linked rituximab) induced significant levels of apoptosis in Ramos (29.2 ± 2.4%) and Daudi (32.8 ± 2.1%) WT cells, whereas cross-linked rituximab moderately killed RR clones (Fig. 1D), suggesting that clones have developed higher threshold (Ramos-RR1, 2.86-fold; Daudi-RR1, 2.56-fold) and, unlike the WT cells, do not efficiently respond to cross-linked rituximab-mediated apoptosis.

Failure to respond to CDC. The ability of rituximab to mediate CDC in RR clones compared with the WT cells was assessed by analyzing the percentage of dead cells that were treated with human AB serum as source of complement (5% or 10%, 24 h). As shown in Fig. 1E, WT cells exhibited modest sensitivity to the cytotoxic effects of AB serum (as a function of serum concentration; Ramos, 15.5 ± 1.3%; Daudi, 14.3 ± 0.9%), an effect that was significantly augmented in the presence of rituximab (Ramos, 36.9 ± 1.5% versus 11.0 ± 0.8%; Daudi, 29.2 ± 1.6% versus 6.2 ± 0.6%). There was augmentation of cytotoxicity with 10% serum than with 5%. However, compared with WT cells, the clones were less sensitive to human AB serum, and rituximab failed to enhance their sensitivity (Ramos-RR1, 14.2 ± 1.6% versus 7.8 ± 0.6%; Daudi-RR1, 11.6 ± 2.4% versus 6.6 ± 1.1%). Increasing serum concentration (15%) neither enhanced their sensitivity nor augmented rituximab-mediated CDC of the clones (data not shown). These results show that WT cells are sensitive to CDC, which is enhanced by both serum levels and rituximab treatment, whereas long-term rituximab exposure is accompanied by higher CDC resistance in the clones (Ramos-RR1, 2.6-fold; Daudi-RR1, 2.5-fold). Moreover, rituximab fails to augment CDC.

Failure of rituximab to chemosensitize the RR clones. Augmentation of the cytotoxic effects of drugs is an established property of rituximab (18). To assess the ability of rituximab to chemosensitize RR clones, WT cells and the clones were pretreated with rituximab, subsequently treated with various concentrations of paclitaxel (0.1–10 nmol/L), and subjected to apoptosis assay. Paclitaxel was used as a representative drug; similar results were obtained with VP-16 and cisplatin (data not shown). Rituximab significantly augmented the apoptotic effect of paclitaxel in WT Ramos and Daudi cells in a concentration-dependent manner (range 45–58% apoptosis; Fig. 1F, left). However, RR clones had higher resistance to paclitaxel, and rituximab was incapable of augmenting paclitaxel-induced apoptosis (Fig. 1F). Higher concentrations of rituximab (2.5- to 5-fold) failed to sensitize the clones (Fig. 1F, right). These results suggest that whereas rituximab efficiently chemosensitizes WT cells, it is incapable of chemosensitizing the clones, which suggests higher resistance of RR clones to rituximab-mediated chemosensitization.

Development of Higher Drug Resistance in RR Clones
Because RR clones were not chemosensitized by rituximab, their sensitivity against a battery of drugs, including paclitaxel, vincristine, VP-16, Adriamycin, and cisplatin, was examined. Compared with WT cells, which exhibit moderate sensitivity to these drugs in a concentration-dependent manner, clones exhibited higher apoptosis threshold to these drugs, albeit to varying degrees. As such, Ramos-RR1 showed 1.54-fold (136%), 1.42-fold (130%), 2.3-fold (158%), 1.8-fold (145%), 1.41-fold (120%) and Daudi-RR1 showed 1.63-fold (139%), 1.66-fold (140%), 1.94-fold (149%), 2.97-fold (167%), 1.95-fold (149%) resistance to paclitaxel, vincristine, Adriamycin, VP-16, and cisplatin, respectively, compared with their respective WT cells (Fig. 2A ). Prolonged incubation time (48 h) did not significantly augment drug cytotoxicity in the clones (data not shown), suggesting that compared with WT cells, RR clones exhibit higher (1.41- to 2.97-fold) drug resistance. Functional analysis of the multidrug resistance (MDR) pump showed the existence of functional MDR pump in both WT cells and the clones. Further, RR clones exhibited no functional impairment of MDR pump (±rituximab; data not shown), suggesting that higher drug resistance of the clones is independent of the MDR pump.


Figure 2
View larger version (30K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Higher drug resistance and overexpression of the antiapoptotic Bcl-2 family members in the RR clones. A, cells (2 x 106) were either left untreated or treated with various concentrations of paclitaxel (1.0, 10, and 20 µg/mL), Adriamycin (0.5, 1.0, and 2.0 µg/mL), cisplatin (CDDP; 1.0, 10, and 20 µg/mL), vincristine (0.1, 0.5, and 1.0 µg/mL), and VP-16 (1.0, 10, and 20 µg/mL) for 18 h. Then, the cells were stained with propidium iodide solution, and apoptosis was assessed by FACS. Samples were set up in duplicates. Columns, mean (n = 2); bars, SD. (Fold drug resistance was measured using the highest percentage of apoptosis induced by the highest concentration of the drug in the WT cells as 100% and calculating the required drug concentration to achieve the same level of apoptosis in the clones.) B, total RNA of various culture conditions was extracted from 107 cells (as indicated) and converted to cDNA. cDNA (2.5 µg) was used in qPCR analysis to determine the transcript levels. Levels of GAPDH were confirmed for equal loading. Columns, mean of triplicate samples; bars, SD. C, whole-cell extracts (40 µg) of WT cells and RR clones (± 20 µg/mL rituximab, 24 h) were subjected to immunoblotting for protein levels. Levels of ß-actin were used for equal loading (n = 2). *, P < 0.05, significant compared with control.

 
Overexpression of Bcl-2, Bcl-xL, and Mcl-1 in RR Clones
RR clones did not respond to rituximab-mediated chemosensitization and exhibited higher drug resistance. Previous findings have established Bcl-xL as an important resistant factor (19, 20); thus, we evaluated Bcl-xL levels and other antiapoptotic Bcl-2 family members in the clones. Total RNA was extracted and converted to first stranded cDNA, which was subjected to real-time quantitative PCR (qPCR) analysis. RR clones exhibited increased expression of Bcl-2 (Ramos-RR1, 3.6-fold; Daudi-RR1, 3.2-fold), Bcl-xL (Ramos-RR1, 8.2-fold; Daudi-RR1, 4.2-fold), Mcl-1 (Ramos-RR1, 3.4-fold; Daudi-RR1, 2.8-fold) at the transcription level (Fig. 2B). Immunoblotting showed that clones exhibit higher Bcl-2, Bcl-xL, and Mcl-1 protein levels (~2.3- to 5.0-fold) compared with WT cells. Interestingly, expression levels of these proteins remained unaffected by rituximab treatment of the clones, whereas Bcl-xL levels in WT cells were reduced (Fig. 2C). Notably, expression levels of other proapoptotic and antiapoptotic factors (Bcl-xS, Bfl-1/A1, Bad, Bax, Bid, Bak, c-IAP-1, c-IAP-2, survivin, XIAP) were similar in WT cells and RR clones (±rituximab; data not shown). These results show that clones express higher levels of protective factors, which may explain their unresponsiveness to rituximab-mediated chemosensitization and higher drug resistance. Also, rituximab was unable to reduce the levels of resistant factors, suggesting that signaling pathways in the clones are no longer responsive to rituximab.

Hyperactivation of the ERK1/2 and NF-{kappa}B Signaling Pathways in the RR Clones
The above findings suggest that the dynamics of the cellular signaling pathways are altered in the clones. Rituximab inhibits ERK1/2 and NF-{kappa}B pathways leading to reduced DNA-binding ability of AP-1 and NF-{kappa}B transcription factors in WT cells (19, 20). Thus, we examined the activation status of these pathways in the clones. Whole-cell extracts of WT cells and the clones (±rituximab) were subjected to immunoblotting for components of NF-{kappa}B and ERK1/2 pathways. The phosphorylation-dependent state of IKK, I{kappa}B-{alpha}, and ERK1/2 was higher in the clones (~3.2- to 4.8-fold) than in WT cells. Basal levels of these signaling molecules remained unaffected in WT and RR clones (± rituximab, data not shown). Rituximab significantly reduces the phosphorylation of these molecules in WT cells (19, 20), an effect that is not observed in clones (Fig. 3A ), suggesting that molecular switches responsible for rituximab-mediated dephosphorylation of these molecules are no longer operative in clones.


Figure 3
View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Hyperactivation of the NF-{kappa}B and ERK1/2 survival pathways in the RR clones. After overnight growth in RPMI 1640 + 1% FBS, RR clones were washed and grown in complete medium ± rituximab (20 µg/mL, 24 h). A, total cell lysates (40 µg) were subjected to Western blot analysis using phosphospecific antibodies for various components of the NF-{kappa}B and ERK1/2 pathways. B, the kinase activity of the IKK complex using I{kappa}B-{alpha} peptide (amino acids 1–50 including S32/36) and ERK1/2 using MAPK kinase substrate 4 (amino acids 172-192) using immunocomplex kinase assay. C, after overnight growth in RPMI 1640 + 1% FBS, cells were washed and were grown in complete medium (± rituximab, DHMEQ, or PD098059). Ten micrograms of nuclear lysates were subjected to EMSA (n = 2; refs. 19, 20).

 
To ascertain the observed hyperphosphorylation results in increased activity of NF-{kappa}B and ERK1/2 pathways, immunocomplex kinase assays were done to assess IKK and MEK1/2 kinase activities of the clones (±rituximab) using I{kappa}B-{alpha} peptide (IKK substrate) and MAPK kinase substrate-4 (ERK1/2 substrate). Untreated clones showed significantly increased kinase activities as shown by increased ability of the lysates to phosphorylate their specific substrates, whereby rituximab did not reduce the IKK and MEK1/2 kinase activities. This phenomenon was not observed by I{kappa}B-{alpha} peptide S32/36A (data not shown). In contrast, in WT cells, rituximab diminishes the kinase activity of IKK and MEK1/2 (Fig. 3B); thus, increased phosphorylation of signaling molecules culminates in higher kinase activity of these pathways in the clones. Next, alterations in the DNA-binding ability of NF-{kappa}B and AP-1 in the clones were examined. Biotin-labeled oligonucleotides probes comprising the NF-{kappa}B (32) and AP-1 (31) consensus binding sites were used in EMSAs, which reveal that, compared with WT cells, NF-{kappa}B and AP-1 DNA-binding abilities are increased in the clones and rituximab fails to reduce their DNA-binding abilities. Rituximab-induced decrease in NF-{kappa}B and AP-1 DNA-binding ability was only observed in WT cells. The specificity of EMSA was corroborated using appropriate controls (Fig. 3C). Specific inhibitors (DHMEQ and PD098059) preferentially reduced NF-{kappa}B and AP-1 DNA-binding abilities. Collectively, these results show that NF-{kappa}B and ERK1/2 pathways are constitutively hyperactivated in RR clones and denote the inability of rituximab to negatively regulate the activities of these pathways in the clones unlike WT cells. Hyperactivation of these pathways will lead to enhanced transcription of their respective antiapoptotic target genes, leading to higher drug resistance of the clones.

Chemosensitization of RR Clones by Pharmacologic Inhibitors of ERK1/2 and NF-{kappa}B Pathways
The NF-{kappa}B and ERK1/2 pathways are hyperactivated in RR clones, leading to overexpression of Bcl-2, Bcl-xL, and Mcl-1, all of which are unaffected by rituximab. This prompted us to investigate whether inhibition of these pathways or Bcl-2 members can reverse chemoresistance. Because these pathways have higher activities in RR clones, higher concentrations of inhibitors were required for chemosensitization of the clones than those used for WT cells, the nontoxic effective concentrations of which were determined by pilot studies (data not shown). Cells were either left untreated or pretreated with DHMEQ (36), bortezomib (37), and PD098059 (33). Escalating concentrations of various drugs were then added, and the percentage of apoptosis was measured. In Ramos-RR1, whereas DHMEQ induces 10.1 ± 2.1% apoptosis, it significantly augments the apoptotic effects of drugs (paclitaxel, 20.4 ± 3.0% -> 46.5 ± 2.3%; Adriamycin, 14.3 ± 3.3% -> 32.4 ± 2.9%; VP-16, 10.3 ± 1.1% -> 53.0 ± 2.6%; cisplatin, 19.0 ± 0.7% -> 61.2 ± 2.1%; vincristine, 15.3 ± 1.1% -> 53.5 ± 2.2%). In Daudi-RR1, DHMEQ induces 4.9 ± 1.6% apoptosis and augments drug efficacy (paclitaxel, 14.9 ± 3.2% -> 42.0 ± 1.9%; Adriamycin, 12.4 ± 2.5% -> 40.5 ± 3.1%; VP-16, 11.8 ± 0.9% -> 32.0 ± 2.2%; cisplatin, 25.7 ± 3.1% -> 36.6 ± 0.9%; vincristine, 14.2 ± 1.7% -> 36.6 ± 2.3%; Fig. 4A–C ). Similar patterns of significant dose-dependent chemosensitization of RR clones were observed; however, for simplicity, only the values pertaining to the highest drug concentration are presented (Table 1A ). Enhanced cytotoxicity by DHMEQ was 2.3- to 5.1-fold and 1.4- to 3.3-fold, by bortezomib was 1.8- to 5.1-fold and 1.7- to 3.3-fold, and by PD098059 was 1.8- to 3.1-fold and 1.5- to 2.7-fold in Ramos-RR1 and Daudi-RR1, respectively (Table 1B). The ability of inhibitors to significantly chemosensitize the RR clones (1.5- to 5.1-fold) suggests that inhibition of NF-{kappa}B and ERK1/2 pathways can avert chemoresistance and rituximab resistance in clones to subtoxic drug concentrations.


Figure 4
View larger version (53K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Chemosensitization of the RR clones by chemical inhibitors. Cells (2 x 106) were either left untreated or pretreated with (A) DHMEQ (WT, 10 µg/mL; clones, 20 µg/mL), (B) bortezomib (WT, 4 µmol/L; clones, 8 µmol/L), or (C) PD098059 (WT, 15 µg/mL; clones, 30 µg/mL) for 2 h. Cells were then incubated with paclitaxel (1.0, 10, and 20 µg/mL), Adriamycin (ADR; 0.5, 1.0, and 2.0 µg/mL), cisplatin (1.0, 10, and 20 µg/mL), vincristine (0.1, 0.5, and 1.0 µg/mL), and VP-16 (1.0, 10, and 20 µg/mL) for an additional 18 h and subjected to DNA fragmentation assay. The samples were set up in duplicates. Columns, mean of two independent experiments; bars, SD. *, P < 0.05, significant compared with drug treatment alone.

 

View this table:
[in this window]
[in a new window]

  		Table 1. Chemosensitization of the RR clones by chemical inhibitors

 
Because inhibitors efficiently chemosensitized the clones, we assessed their effect on expression of the resistant factors. As depicted by qPCR inhibitors, mRNA levels of Bcl-2, Bcl-xL, and Mcl-1 were reduced by 1.2- to 4.8-fold and 1.2- to 6.6-fold (Fig. 5A ), and immunoblots showed 1.25- to 3.3-fold and 1.1- to 3.3-fold decreases in their protein levels in Ramos-RR1 and Daudi-RR1, respectively (Fig. 5B), further suggesting the involvement of NF-{kappa}B and ERK1/2 pathways in the expression of resistant factors.


Figure 5
View larger version (47K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Inhibition of the expression of antiapoptotic factors by chemical inhibitors. RR1 clones were either left untreated or treated with DHMEQ (20 µg/mL), bortezomib (8.0 µmol/L), and PD098059 (30 µg/mL). A, 2.5 µg cDNA was used in qPCR using gene-specific primers. Levels of GAPDH were confirmed for equal loading. Samples were set up in duplicates. Columns, mean (n = 2); bars, SD. B, total cell lysates (40 µg) were subjected to immunoblotting for Bcl-2, Bcl-xL, and Mcl-1. Levels of ß-actin were used for equal loading (n = 2). C, role of antiapoptotic Bcl-2 members in chemosensitization. Cells were either left untreated or pretreated with 2MAM-A3 (WT, 15 µg/mL; clones, 35 µg/mL, 7 h). The cells were then washed, treated with paclitaxel (10 nmol/L, 18 h), and subjected to DNA fragmentation assay. Samples were set up in duplicates. Columns, mean of two independent experiments; bars, SD. *, P < 0.05, significant compared with paclitaxel alone.

 
The chemoprotective role of the overexpressed Bcl-2, Bcl-xL, and Mcl-1 in clones was further confirmed by pretreatment with 2MAM-A3 (38), which chemosensitized the clones at levels comparable with those achieved by rituximab. In WT Ramos, 2MAM-A3 augmented paclitaxel cytotoxicity by 1.96-fold (13.6 ± 1.3% -> 26.7 ± 2.2%), which was 4.71-fold (8.42 ± 2.1% -> 39.7 ± 2.4%) in Ramos-RR1. A similar pattern was observed in Daudi (WT, 1.98-fold; RR1, 3.2-fold; Fig. 5C). These findings support our contention that overexpression of antiapoptotic Bcl-2 members upon prolonged rituximab treatment protects the cells against drug-induced apoptosis and that their functional impairment is critical for chemosensitization.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
This is the first report on the establishment of B-NHL RR clones, which exhibit a different phenotypic profile compared with WT cells. Using various biochemical and functional assays, compared with WT cells, RR clones express lower levels of surface CD20 and do not respond to growth inhibition by rituximab, rituximab-mediated CDC, or cross-linked rituximab-induced apoptosis. Further, RR clones are not chemosensitized by rituximab and exhibit higher drug resistance (1.41- to 2.97-fold). Two major survival pathways (NF-{kappa}B and ERK1/2) are constitutively hyperactivated in the clones, leading to overexpression of resistant factors (Bcl-2, Bcl-xL, Mcl-1; ~2.3- to 5.0-fold). Pharmacologic inhibition of Bcl-2 family members (by 2MAM-A3), NF-{kappa}B (by DHMEQ, bortezomib), and ERK1/2 pathways (by PD098059) averts the drug-resistant phenotype, and the clones undergo apoptosis in response to low concentrations of various drugs (Fig. 6 ).


Figure 6
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. Proposed model of the development of RR in NHL B-cells. Among other mechanisms (18), alteration in the dynamics of cell signaling, via an elusive mechanism, is a potential mechanism for the development of resistance to rituximab therapy. Continuous long-term rituximab exposure results in the development of NHL B-cell clones that exhibit diminished CD20 surface expression. Compared with the parental cells, the clones exhibit significantly lower sensitivity to CDC-mediated killing; apoptosis induced by cross-linked rituximab; and higher levels of p-I{kappa}B-{alpha}, p-IKK, and p-ERK1/2 correlating with higher IKK and ERK1/2 kinase activities, leading to higher DNA-binding ability of AP-1 and NF-{kappa}B, and culminating in increased Bcl-2, Mcl-1, and Bcl-xL expression. Hyperactivation of these pathways will increase the proliferation rate of the clones; increase the levels of Bcl-2, Bcl-xL, Mcl-1, and the apoptosis threshold; and cause higher chemoresistance of the NHL B-cell clones. Specific pharmacologic inhibition of NF-{kappa}B and ERK1/2 pathways, or functional impairment of antiapoptotic Bcl-2 family members, averts the acquired chemoresistance phenotype of the RR clones, inducing the cells to undergo apoptosis in response to low levels of drugs.

 
Reducing the proliferation rate of tumor cells is postulated as one of the potential modes of action of rituximab (16, 17). Rituximab treatment of WT cells reduces their growth rate (28); however, the clones grew at similar rates as WT cells and rituximab (even at 2.5- to 5.0-fold higher concentrations) was incapable of inhibiting their growth (Fig. 1B) consistent with the higher growth rate and progressive nature of relapsed lymphomas, suggesting that RR clones have lost the ability to undergo rituximab-mediated growth reduction possibly through a defective ceramide acid sphingomyelinase (A-SMase) pathway (39). Compared with WT cells, RR clones exhibit higher resistance to CDC. Rituximab pretreatment significantly enhanced CDC in WT cells—an effect that was not noticed in the clones. Increasing serum concentrations enhanced rituximab-mediated CDC in WT cells but not in clones (Fig. 1D), consistent with our preliminary findings that show increased expression of complement inhibitors on the clones (data not shown). Further studies are warranted to delineate the role of complement inhibitors in CDC resistance of the RR clones. Cross-linked rituximab induced significant apoptosis (Fig. 1E) and cytostasis (data not shown) on WT cells. Neither induction of apoptosis nor growth inhibition was observed on treatment of the clones with cross-linked rituximab, suggesting that RR clones have developed higher threshold in response to biological effects of cross-linked rituximab. The above effects were independent of rituximab concentration as higher (2.5- to 5-fold) concentrations of rituximab failed to reverse the phenotype of the clones (Fig. 1).

Rituximab binds to B-cell–restricted cell surface CD20, thus exerting its effects. Various mechanisms are postulated for rituximab resistance including transient CD20 down-regulation (40), loss of CD20 (41), and circulating CD20 (42). Substantial CD20 surface expression was detected on WT cells; still, RR clones exhibited ~50% reduction in surface CD20 expression (Fig. 1A). The significance of reduced CD20 expression in clones requires further investigation as several lines of evidence suggest that the biological effects of rituximab therapy is autonomous of the intensity of surface CD20 even in vivo (40). Thus, failure of rituximab to exert its biological effects on RR clones may be independent of diminished CD20. It may be due to the activation status of the clones and/or aberrant cellular signaling as deregulation of the signaling pathways or aberrant expression of signaling molecules contribute to acquired chemoresistance (42, 43). Analysis of the signaling pathways in the clones revealed hyperactivation of ERK1/2 and NF-{kappa}B pathways leading to overexpression of their downstream resistant factors Bcl-2, Bcl-xL, and Mcl-1, and the exhibition of higher drug resistance (1.41- to 2.97-fold) concordant with the protective role of Bcl-2 family members (44–46), suggesting that the selective pressure applied by prolonged rituximab treatment has coselected for cells that express higher levels of antiapoptotic proteins which have lost the capacity to undergo apoptosis in response to various stimuli. The possibility of the preexistence of resistant cells in the native culture is not ruled out. Clearly, rituximab has not altered the biological properties of 100% of the cells. However, the resistant subclones in native culture will dominate the sensitive population on long-term rituximab treatment as the sensitive cells will be eliminated over time. However, there is no unequivocal evidence, as yet, that this is the dominant mechanism in vivo. Because drugs use apoptosis as a means of exerting their effects, drug-resistant tumors develop cross-resistance to apoptosis induced by structurally and functionally distinct stimuli, including immunotherapy and vice versa. Thus, as NHL cells develop resistance to rituximab, they may also develop cross-resistance to drugs and the immune system, consistent with our observation that drug-resistant RR clones also exhibit higher resistance to TNF-related apoptosis-inducing ligand (TRAIL) and anti-Fas agonistic antibody (47). Rituximab pretreatment of WT cells, not the clones, efficiently sensitized them to drugs and TRAIL (47).

Unlike WT cells (19, 20), rituximab was incapable of inhibiting hyperactivated NF-{kappa}B and ERK1/2 pathways in the clones. Thus, it is logical to speculate that constitutive hyperactivation of these pathways confer higher drug resistance (21, 22); hence, their inhibition could potentially avert the chemoresistance, prompting us to evaluate the chemosensitizing effects of specific inhibitors of NF-{kappa}B and ERK1/2 pathways as well as bortezomib (Velcade; ref. 37). DHMEQ is a unique inhibitor of NF-{kappa}B acting at the level of nuclear translocation, completely inhibits NF-{kappa}B DNA-binding ability, inhibits the growth of human hormone-refractory prostate and bladder cancer cells, and induces apoptosis at high concentrations (36, 48). PD098059 exerts its effects by specifically binding to inactive form of MEK1/2 and prevents its activation by Raf-1, thus inhibiting ERK1/2 activation (33). Bortezomib is approved for the treatment of multiple myeloma and has significant single-agent activity against certain subtypes of NHL (49). These inhibitors efficiently sensitized the RR clones to structurally and functionally distinct drugs, including topoisomerase II inhibitor, DNA alkylating agents, and microtubule poisons, albeit to varying degrees (Table 1). The inhibitors also reduced Bcl-2, Bcl-xL, and Mcl-1 levels, further suggesting that deregulated signaling culminates in overexpression of antiapoptotic proteins in RR clones, which then leads to higher drug resistance. The chemoprotective role of Bcl-2 family members was confirmed by using 2MAM-A3, a specific inhibitor that binds to the hydrophobic groove formed by the highly conserved BH1, BH2, and BH3 domains, thus impairing the function of Bcl-2, Bcl-xL, and Mcl-1 (38). 2MAM-A3 efficiently chemosensitized the clones, further attesting that higher expression of resistant factors protects RR clones from drug-induced apoptosis. Hence, aberrations in the normal dynamics of cellular survival pathways upon continuous rituximab exposure contribute to acquired rituximab and/or drug resistance, whereas interruption of these pathways leads to chemosensitization of RR clones. Thus, functional impairment of antiapoptotic proteins is critical for reversion of chemoresistance.

The nature of the molecular cues that trigger the aberrant activation of survival pathways in the clones, hence their altered phenotype, are unclear at present. In WT Daudi, rituximab induces a rapid and transient increase in A-SMase activity parallel with cellular ceramide generation in lipid rafts. These cells externalize both ceramide and A-SMase, which colocalize with CD20. Also, rituximab-induced growth inhibition may be mediated through a ceramide-dependent pathway (39). Preliminary observations suggest that rituximab-induced A-SMase translocation and ceramide generation at cell surface are reduced in clones (50). Because microdomains serve as signaling platforms, these data suggest that rituximab resistance in clones is partly due to faulty mobilization of the signaling molecules to lipid rafts and a crippled ceramide/A-SMase pathway. These possibilities are currently under scrutiny.

The present findings are the first report on the establishment of an in vitro model of RR NHL clones, which shows that repeated rituximab exposure results in loss of the ability of rituximab to regulate molecular switches leading to constitutive hyperactivation of survival pathways, overexpression of resistant factors, and increased apoptosis threshold. Accordingly, rituximab fails to exert antilymphoma effects and RR clones develop higher drug resistance, which may explain the treatment-refractory and the aggressive nature of clinical rituximab-resistant and drug-resistant NHL. Figure 6 shows the potential mechanisms of RR. The observed drug resistance and rituximab resistance of RR clones mimic those previously observed (27). However, RR clones are still amenable to chemotherapy using specific molecular targeting of the components of deregulated pathways. Our studies identify several such targets for potential molecular intervention in the treatment of rituximab-resistant and drug-resistant NHL. Analysis of dynamics of survival pathways in patient-derived specimens may also serve as biomarkers in choosing treatment options. Such patients may be suitable candidates for alternative (e.g., targeted therapy) over conventional regimens. Studies are under way to validate our in vitro findings with freshly derived RR specimens and to establish RR mouse model.


   Acknowledgments
 
Grant support: University of California-Los Angeles AIDS Institute, University of California-Los Angeles Center for AIDS Research grant AI28697, State of California Universitywide AIDS Research Program grant CC02-LA-001, fellowship awards from the Jonnson Comprehensive Cancer Center at University of California-Los Angeles (A.R. Jazirehi and M.I. Vega), Fogarty International Center Fellowship D43TW00013 (M.I. Vega), and a philanthropic contribution from The Ann C. Rosenfield Fund under the direction of David A. Leveton.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Stavroula Baritaki for technical assistance.


   Footnotes
 
1 http://rsb.info.nih.gov/nih-image/. Back

Received 6/14/06. Revised 10/30/06. Accepted 11/29/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435–5.[Abstract/Free Full Text]
  2. Coiffier B, Pfreundschuh M, Stahel R, Vose J, Zinzani PL. Aggressive lymphoma: improving treatment outcome with rituximab. Anticancer Drugs 2002;2:S43–50.
  3. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450–4.[CrossRef][Medline]
  4. Andeson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424–33.[Abstract/Free Full Text]
  5. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584–91.[Abstract/Free Full Text]
  6. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711–7.[Medline]
  7. Grillo-Lopez AJ. Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol 2002;76:385–93.[Medline]
  8. Dillman RO. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin Oncol 2003;30:434–47.[CrossRef][Medline]
  9. Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003;30:483–92.[CrossRef][Medline]
  10. Hiddemann W, Dreyling M, Unterhalt M. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 2003;30:16–20.[CrossRef][Medline]
  11. Ghobrial IM, Gertz MA, Fonseca R. Waldensrtrom macroglobulinemia. Lancet Oncol 2003;4:679–85.[CrossRef][Medline]
  12. Risken NP, Keuning JJ, Vreugdenhil G. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura. Neth J Med 1993;61:262–5.
  13. Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003;26:351–4.
  14. Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003;124:1242–9.
  15. Weichert ZG, Martinka M, Rivers JK. Intravascular lymphoma presenting as telangectasias: response to rituximab and combination chemotherapy. J Cutan Med Surg 2003;7:460–3.[Medline]
  16. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005;23:6421–8.[Abstract/Free Full Text]
  17. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359–68.[CrossRef][Medline]
  18. Jazirehi AR, Bonavida B. Molecular and cellular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: mplications in chemo-sensitization and therapeutic. Oncogene 2005;24:2121–43.[CrossRef][Medline]
  19. Jazirehi AR, Vega M, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemo-sensitization of non-Hodgkin's lymphoma B-cells by Rituximab. Cancer Res 2004;64:7117–26.[Abstract/Free Full Text]
  20. Jazirehi AR, Huerta S, Cheng G, Bonavida B. Rituximab (chimeric anti -CD20 mAb) inhibits the constitutive NF-{kappa}B signaling pathway in non-Hodgkin's lymphoma (NHL) B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005;65:264–76.[Abstract/Free Full Text]
  21. Ghosh S, Karin M. Missing pieces in the NF-{kappa}B puzzle. Cell 2002;109:S81–96.
  22. Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res 2001;7:775–83.[Free Full Text]
  23. Wang CU, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemo-resistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kB. Nat Med 1999;5:412–7.[CrossRef][Medline]
  24. Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NF-kB, STAT and AP-1 transcription factor families. Histol Histopathol 2001;16:595–01.[Medline]
  25. Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 2006;91:715–6.[Abstract/Free Full Text]
  26. Jazirehi AR, Bonavida B. Cellular and molecular characterization of rituximab-resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) clones: development of cross-resistance to cytotoxic stimuli [abstract presented during the 2004 ASH meeting]. Blood 2004;104:3410.[Free Full Text]
  27. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Loss of expression of the pro-apoptotic Bcl-2 family proteins Bak and Bax in rituximab- and chemotherapy-resistant non-Hodgkin's lymphoma cells [abstract presented during the 2005 ASH meeting]. Blood 2005;106:4819.
  28. Jazirehi AR, Gan X-H, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and Apaf-1 expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003;2:1183–93.[Abstract/Free Full Text]
  29. Nicoletti IG, Migliorati MC, Pagliacci F, Grignani C, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271–9.[CrossRef][Medline]
  30. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity using human and other tumor cell lines. Cancer Res 1998;48:4827–33.
  31. Lee W, Mitchell P, Tijan R. Purified transcription factor AP-1 interacts with TPA inducible enhancer elements. Cell 1987;49:741–52.[CrossRef][Medline]
  32. Harada H, Takahashi EI, Itoh S, Harada K, Hori TA, Taniguchi T. Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a network in the interferon system. Mol Cell Biol 1994;14:1500–9.[Abstract/Free Full Text]
  33. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489–94.[Abstract/Free Full Text]
  34. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995–1001.[Abstract/Free Full Text]
  35. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with mAbs. Blood 1998;91:1644–52.[Abstract/Free Full Text]
  36. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-{alpha}-induced nuclear translocation and activation of NF-{kappa}B by dehydroxymethylepoxyquino- micin. J Biol Chem 2002;277:24626–30.
  37. Goy A, Gilles F. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin Lymphoma 2004;4:230–7.[Medline]
  38. Tzung S-P, Kim CM, Basanez G, et al. Antimycin A mimics a cell death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001;3:183–91.[CrossRef][Medline]
  39. Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004;104:1166–73.[Abstract/Free Full Text]
  40. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280–8.[Abstract/Free Full Text]
  41. Haidar JH, Shamseddine A, Salem Z, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003;70:330–2.[CrossRef][Medline]
  42. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:2507–13.[Abstract/Free Full Text]
  43. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemo-therapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934–49.[CrossRef][Medline]
  44. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004;23:2838–49.[CrossRef][Medline]
  45. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of Bcl-xL can confer a multi-drug resistance phenotype. Blood 1995;86:1903–10.[Abstract/Free Full Text]
  46. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Jr., Fornace A. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101–10.[Abstract/Free Full Text]
  47. Jazirehi AR, Bonavida B. Sensitization of rituximab-sensitive and rituximab-resistant B-NHL cell lines/clones to TRAIL-induced apoptosis by Bortezomib and NF{kappa}B inhibitors. Blood 2005;106:1514.[Free Full Text]
  48. Kikuchi E, Horiguhi Y, Nakashima J, et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor {kappa}B inhibitor in nude mice. Cancer Res 2003;63:107–10.[Abstract/Free Full Text]
  49. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676–84.[Abstract/Free Full Text]
  50. Jazirehi AR, Bezombes C, Laurant G, Libra M, Bonavida B. Characteristics of rituximab-resistant B-NHL clones: deficiencies in rituximab-mediated changes in lipid raft micro-domains and cell signaling. Proc AACR 2006;47:4657.



This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Baritaki, K. Yeung, M. Palladino, J. Berenson, and B. Bonavida
Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
Cancer Res., November 1, 2009; 69(21): 8376 - 8385.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. A. Thomas, S. O'Brien, J. L. Jorgensen, J. Cortes, S. Faderl, G. Garcia-Manero, S. Verstovsek, C. Koller, S. Pierce, Y. Huh, et al.
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
Blood, June 18, 2009; 113(25): 6330 - 6337.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H.-P. Gerber, M. Kung-Sutherland, I. Stone, C. Morris-Tilden, J. Miyamoto, R. McCormick, S. C. Alley, N. Okeley, B. Hayes, F. J. Hernandez-Ilizaliturri, et al.
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
Blood, April 30, 2009; 113(18): 4352 - 4361.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Terui, Y. Mishima, N. Sugimura, K. Kojima, T. Sakurai, Y. Mishima, R. Kuniyoshi, A. Taniyama, M. Yokoyama, S. Sakajiri, et al.
Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma
Clin. Cancer Res., April 1, 2009; 15(7): 2523 - 2530.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Dalle, S. Dupire, S. Brunet-Manquat, L. Reslan, A. Plesa, and C. Dumontet
In vivo Model of Follicular Lymphoma Resistant to Rituximab
Clin. Cancer Res., February 1, 2009; 15(3): 851 - 857.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Z. Meng, N. Mitsutake, M. Nakashima, D. Starenki, M. Matsuse, S. Takakura, H. Namba, V. Saenko, K. Umezawa, A. Ohtsuru, et al.
Dehydroxymethylepoxyquinomicin, a Novel Nuclear Factor-{kappa}B Inhibitor, Enhances Antitumor Activity of Taxanes in Anaplastic Thyroid Cancer Cells
Endocrinology, November 1, 2008; 149(11): 5357 - 5365.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Stolz, G. Hess, P. S. Hahnel, F. Grabellus, S. Hoffarth, K. W. Schmid, and M. Schuler
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
Blood, October 15, 2008; 112(8): 3312 - 3321.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
X. Zhou, W. Hu, and X. Qin
The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
Oncologist, September 1, 2008; 13(9): 954 - 966.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al.
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
Ann. Onc., March 1, 2008; 19(3): 560 - 565.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. H. Olejniczak, F. J. Hernandez-Ilizaliturri, J. L. Clements, and M. S. Czuczman
Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression
Clin. Cancer Res., March 1, 2008; 14(5): 1550 - 1560.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Czuczman, S. Olejniczak, A. Gowda, A. Kotowski, A. Binder, H. Kaur, J. Knight, P. Starostik, J. Deans, and F. J. Hernandez-Ilizaliturri
Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
Clin. Cancer Res., March 1, 2008; 14(5): 1561 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Powles, J. Stebbing, S. Montoto, M. Nelson, B. Gazzard, C. Orkin, A. Webb, and M. Bower
Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease
Blood, December 1, 2007; 110(12): 4132 - 4133.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
C. Bello and E. M. Sotomayor
Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond
Hematology, January 1, 2007; 2007(1): 233 - 242.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jazirehi, A. R.
Right arrow Articles by Bonavida, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jazirehi, A. R.
Right arrow Articles by Bonavida, B.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online